Opioid Use Disorder: Buprenorphine Induction and Maintenance Evidence

Extended-Release Injectable Buprenorphine

Sublocade (extended-release buprenorphine injection) administered monthly subcutaneously provides steady-state plasma levels and eliminates daily dosing adherence barriers. The pivotal trial demonstrated 43.0% cumulative abstinence from illicit opioids (300 mg dose) versus 5.0% with placebo[7]. After stabilization on sublingual buprenorphine (8 mg or above for 7 days), patients receive 300 mg monthly for the first two months followed by maintenance doses of 100-300 mg. Extended-release formulations also reduce diversion risk, a consideration in high-risk treatment settings.

Treatment Duration and Harm Reduction Integration

Evidence strongly supports indefinite MOUD continuation: patients who discontinue buprenorphine have relapse rates exceeding 80% within the first year[8]. The optimal approach is ongoing treatment without a predetermined endpoint, with individualized taper consideration only for patients with sustained recovery, strong social supports, and informed consent regarding relapse risk. Concurrent depression treatment improves retention in care. Integration with harm reduction (naloxone co-prescribing, fentanyl test strip access, and safe supply programs) should be standard, alongside management of common comorbidities such as hepatitis C and HIV. All patients on buprenorphine should receive a naloxone prescription for household members and close contacts.

Overcoming Prescribing Hesitancy

Despite the elimination of the X-waiver, many primary care physicians remain hesitant to prescribe buprenorphine — citing concerns about attracting a difficult patient population, insufficient training, or lack of counseling support. These concerns, while understandable, should be weighed against the reality that OUD patients are already in every primary care panel, often presenting with pain, hepatitis C, recurrent infections, or emergency department visits that could be prevented by effective MOUD. The prescribing itself is straightforward — simpler than managing anticoagulation or insulin titration. The most impactful barrier to overcome is the first prescription: clinicians who start one patient on buprenorphine and see the dramatic improvement in that patient's stability, health engagement, and quality of life are rarely hesitant to prescribe it again.

Limitations and Ongoing Challenges

The evidence for buprenorphine's mortality reduction is robust but derived from observational studies — randomized trials of MOUD versus no treatment are ethically impossible given the known mortality benefit. The fentanyl-predominant drug supply has complicated traditional induction protocols, as patients using illicitly manufactured fentanyl may have prolonged and unpredictable withdrawal timelines that make standard COWS-based induction timing unreliable. Micro-dosing protocols address this but are supported by retrospective and small prospective data rather than large RCTs. Treatment retention remains a persistent challenge, with many patients discontinuing within the first year despite the known relapse risk. And the stigma surrounding MOUD — from patients, families, and clinicians alike — remains the most fundamental barrier to closing the treatment gap.

References

1. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
2. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
3. Consolidated Appropriations Act, 2023 (Section 1262 - MATE Act provisions)
4. SAMHSA Buprenorphine Clinical Guidelines
5. The Bernese method of buprenorphine induction
6. Buprenorphine microdosing: a systematic review and meta-analysis
7. A Phase 3, Randomized, Controlled Study of Monthly Subcutaneous Buprenorphine Depot Injection (RBP-6000/BUP-XR) in the Treatment of Opioid Use Disorder
8. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes